TCM
VNDA icon

Timpani Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Timpani Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-49,227
Closed -$800K – 91
2014
Q1 		$800K Buy
+49,227
New +$700K 0.42% 76

Other funds holding VNDA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
SCA
Signpost Capital Advisors New York $34.2M AUM 5.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Timpani Capital Management's VNDA Position: Q2 2014 in Review

Timpani Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2014, closing a stake of 49,227 shares — an estimated $800K sold.

Timpani Capital Management first reported a position in VNDA in Q1 2014 and held it in 1 quarter. The position peaked at $800K in Q1 2014. 110 funds tracked by Wall St. Rank hold VNDA as of Q2 2014.

  • Timpani Capital Management reported no remaining Vanda Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Timpani Capital Management sold 49,227 Vanda Pharmaceuticals shares in Q2 2014, an estimated $800K.
  • Timpani Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Timpani Capital Management's Vanda Pharmaceuticals position peaked at $800K in Q1 2014.
  • 110 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2014.

Based on Timpani Capital Management's 13F filing for Q2 2014, filed 5 Aug 2014.